What is Faruqi & Faruqi investigating about Beta Bionics, Inc.?

Faruqi & Faruqi is investigating whether Beta Bionics, Inc. made misleading statements or failed to disclose important information to investors, potentially violating federal securities laws and contributing to investor losses.

Why did Beta Bionics stock drop sharply in January 2026?

Beta Bionics stock fell about 37% on January 9, 2026 after the company announced it expected fewer patient starts in the fourth quarter than analysts had projected, surprising the market.

Who may be affected by the Beta Bionics securities investigation?

Investors who purchased or held Beta Bionics (NASDAQ: BBNX) shares before the January 2026 stock drop may be affected, especially if they relied on company statements later alleged to be misleading.

may be affected, especially if they relied on company statements later alleged to be misleading. What types of claims are being examined against Beta Bionics?

The investigation focuses on potential securities fraud claims, including whether the company misrepresented its business outlook or failed to timely disclose negative operational information to investors.

What does Faruqi & Faruqi do in securities investigations like this?

Faruqi & Faruqi investigates potential violations of securities laws, represents investors in class actions or individual claims, and seeks to recover financial losses caused by misleading corporate disclosures.

Beta Bionics, Inc. - Faruqi & Faruqi LLP

Beta Bionics, Inc.

Join Action

If you are a Beta Bionics, Inc. investor who suffered a loss and would like to learn more, you can provide your information below

If you suffered significant losses in Beta Bionics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).

STOCK DROP: On January 9, 2026, shares of Beta Bionics declined sharply in trading, following the company’s disclosure of preliminary fourth-quarter 2025 performance metrics that fell short of market expectations.

The company reported lower-than-anticipated new patient starts for its iLet automated insulin delivery system, prompting investor concerns regarding near-term adoption trends and revenue growth.

On this news, Beta Bionics stock fell roughly $11.85 or 37.04% to close at $20.14, on January 9, 2026.

Join Action

Beta Bionics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify